scholarly journals Clinicopathologic Features and Survival Outcomes of Signet Ring Cell Carcinoma of the Appendix: An Analysis of the Surveillance, Epidemiology, and End Results Database

Cureus ◽  
2020 ◽  
Author(s):  
Kamelah Abushalha ◽  
Wa'el Tuqan ◽  
Sara A Albagoush ◽  
Sawsan Abulaimoun ◽  
Peter T Silberstein
Keyword(s):  
Cell Carcinoma ◽  
Signet Ring Cell Carcinoma ◽  
Signet Ring Cell ◽  
Survival Outcomes ◽  
Clinicopathologic Features ◽  
Signet Ring ◽  
Ring Cell ◽  
End Results

scholarly journals Clinicopathologic Features of Signet-ring Cell Carcinoma of the Colon and Rectum

2006 ◽  
Vol 39 (1) ◽  
pp. 16-22 ◽  
Author(s):  
Tomoki Makino ◽  
Hideyuki Mishima ◽  
Masakazu Ikenaga ◽  
Toshimasa Tsujinaka ◽  
Masashi Takeda ◽  
...  
Keyword(s):  
Cell Carcinoma ◽  
Signet Ring Cell Carcinoma ◽  
Signet Ring Cell ◽  
Clinicopathologic Features ◽  
Carcinoma Of The Colon ◽  
Signet Ring ◽  
Colon And Rectum ◽  
Ring Cell

Prognostic value of tumor-infiltrating lymphocytes in signet-ring cell carcinoma of the rectum and sigmoid colon.

2021 ◽  
Vol 39 (15_suppl) ◽  
pp. e15079-e15079
Author(s):  
Jiaolin Zhou ◽  
Jia Wang ◽  
Yaping Xu ◽  
Guole Lin ◽  
Huanwen Wu ◽  
...  
Keyword(s):  
Cell Carcinoma ◽  
Sigmoid Colon ◽  
Tumor Infiltrating Lymphocytes ◽  
Signet Ring Cell Carcinoma ◽  
Signet Ring Cell ◽  
Stage Ii ◽  
Survival Outcomes ◽  
Signet Ring ◽  
Ring Cell ◽  
Infiltrating Lymphocytes

e15079 Background: Signet-ring cell carcinoma (SRCC) of rectum and sigmoid colon is an extremely rare subtype of colorectal cancer (CRC) with very poor prognosis. Tumor-infiltrating lymphocytes (TILs) signify the host immune response to tumors, which were reported to predict survival outcomes of patients with various cancer types. In this study, we aimed to characterize TILs and mutational features of SRCC of rectum and sigmoid colon as well as their correlations with the clinicopathological parameters and survival outcomes. Methods: 28 patients with stage II-IV SRCC of rectum and sigmoid colon were included, in which 12 patients had tumors with ≥50% signet-ring cells (SRCs) and 16 had tumors with <50% SRCs. Targeted next generation sequencing using a 1,021-gene panel was used to investigate the genetic alterations of tumor tissue. Multiplex immunofluorescence assays were performed to visualize TILs. TILs within cancer cell nests (iTILs) and in cancer stroma (sTILs) were counted separately. The correlations of TILs with survival outcomes were analyzed in stage II/III patients who underwent the radical resection. Results: Somatic alterations were detected in all the 28 cases. The most frequently mutated genes included TP53, APC and SMAD4, occurring in 68%, 36% and 36% of cases, respectively. BRAF mutation were detected in only one patient (3.6%). The median tumor mutational burden (TMB) was 4.80 (range, 0.96-42.24) muts/Mb. Three patients (10.7%) were with microsatellite instability-high (MSI-H) status and a high TMB of more than 10 muts/Mb. Patients with stage IV tumors have significantly lower PD-1+ CD8+ iTILs and sTILs (p=0.018 for both), CD8+ iTILs (p=0.022), and PD-1+ iTILs (p=0.013) levels than those with stage II/III tumors. Tumors with ≥ 50% SRCs showed lower levels of CD8+ sTILs than those with < 50% SRCs (p=0.046). Patients with CEA>5.0 ng/ml showed significantly lower levels of PD-1+ CD8+ iTILs than those with CEA≤5.0 ng/ml (p=0.015). Moreover, significantly lower levels of PD-1+ CD8+ sTILs (p=0.036) were observed in tumors that appeared as long circumferential thickening of the bowel wall with stenosis compared to those did not. Multivariate analysis indicated that patients with high PD-1+ CD8+ iTILs and sTILs levels had significantly better disease-free survival (DFS) than those with low PD-1+ CD8+ iTILs and sTILs levels (not reached vs. 22 months for both; p=0.008 and 0.003, respectively). High PD-1+ CD3+ sTILs levels were associated with significantly longer overall survival (OS) compared to low levels (not reached vs. 39 months, p=0.034). No correlation between MSI or TMB and DFS or OS was observed in this small cohort. Conclusions: Our results demonstrated that PD-1+ CD8+ iTILs and sTILs are powerful independent predictors of survival outcomes in patients with resectable SRCC of rectum and sigmoid colon. Further investigations in larger cohorts are needed to validate our findings.

scholarly journals CLINICOPATHOLOGIC FEATURES OF SIGNET-RING CELL CARCINOMA OF THE COLON AND RECTUM

2005 ◽  
Vol 66 (12) ◽  
pp. 2915-2920 ◽  
Author(s):  
Junichi GOTOH ◽  
Kengo KITA ◽  
Masato FUJIYOSHI ◽  
Gentaro HIROKATA ◽  
Koji IMAI ◽  
...  
Keyword(s):  
Cell Carcinoma ◽  
Signet Ring Cell Carcinoma ◽  
Signet Ring Cell ◽  
Clinicopathologic Features ◽  
Carcinoma Of The Colon ◽  
Signet Ring ◽  
Colon And Rectum ◽  
Ring Cell

scholarly journals Resectable gastric signet ring cell carcinoma: clinicopathological characteristics and survival outcomes

2020 ◽  
Vol 2 (3) ◽  
Author(s):  
Ines Zemni ◽  
Houyem Mansouri ◽  
Ines Ben Safta ◽  
Mohamed Ali Ayadi ◽  
Tarek Ben Dhiab ◽  
...  
Keyword(s):  
Cell Carcinoma ◽  
Survival Rates ◽  
Clinicopathological Characteristics ◽  
Signet Ring Cell Carcinoma ◽  
Signet Ring Cell ◽  
Survival Outcomes ◽  
Depth Of Invasion ◽  
Significant Difference ◽  
Signet Ring ◽  
Ring Cell

Background: Gastric signet ring cell carcinoma (SRCC) appears to have clinical features and survival rates particularly different from other histological types. The aim of this study was to investigate clinicopathological features and survival outcomes of SRCC and to compare them with non-signet ring cell carcinoma (NSRCC). Methods: We retrospectively studied 145 patients with non-metastatic gastric carcinoma who underwent gastrectomy in our institute from 2005 to 2015. Among them, 36 patients (9.4%) with SRCC were compared to 109 patients (90.6%) with NSRCC. Results: Patients with SRCC presented at a younger age (p=0.001) with more advanced stage III-IV disease (p=0.005) and advanced N stages with a higher rate of pN3 (p=0.0001), a higher number of invaded lymph nodes (p=0.002) and a higher rate of patients with a lymph node ratio exceeding 25% (63.9% vs 36.7, p=0.004). After a median follow up of 35.30 months, there was no significant difference in the 5 years overall (OS) survival between SRCC and NSRCC ((36.7% vs 45.7%, p=0.206).However, the 5 years progressive free survival (PFS) was significantly decreased in case of SRCC (38.7% vs 50.9%, p=0.038) with a higher rate of metastasis in (52.9% vs 29.5%, p=0.013) and peritoneal recurrence (35.3% vs 9.5%, p<0.0001). The main prognostic factors of PFS and OS in SRCC were tumoral stenosis, hypoprotidemia, tumor size, depth of invasion (p=0.001), perineural and lymphovascular invasion, the UICC stage and complete surgical resection. Conclusion: Gastric SRCC have a particular clinicopathological behavior compared to NSRCC suggesting its more aggressive character.

Sign in / Sign up

Export Citation Format

Share Document